Drug therapy for macular oedema treatment approved
Ozurdex, the first drug therapy for the treatment of macular oedema, following branch retinal vein occlusion or central retinal vein occlusion, has been approved by the FDA.
Ozurdex, the first drug therapy for the treatment of macular oedema, following branch retinal vein occlusion or central retinal vein occlusion, has been approved by the FDA.
It comprises a biodegradable, injectable steroid implant with extended drug release. It is administered via intravitreal injection and delivers extended release of a highly potent corticosteroid using the company's proprietary solid polymer delivery system, Novadur.
"Ozurdex represents the first injectable, sustained release, potent steroid implant that provides prolonged efficacy and a favourable safety profile. In clinical studies, 20-30% of patients suffering from this retinal condition experienced a 3-line improvement in best-corrected visual acuity with an onset of effect within the first two months following therapy," said Scott Whitcup, Allergan's executive vice president, R&D and chief scientific officer.
